Year 1: 1,299,000.00 Year 2: 501,000.00
New drugs for Bad Bugs
Biolytx Pharmaceuticals Corporation
The high mortality rate of hospital-acquired pneumonia results from the growing tide of antibiotic-resistant bacteria. Few effective drugs are available, treatment can be life-threatening, and cost to the domestic economy exceeds $5B per year. Traditional efforts to counter antibiotic resistance have relied upon making incremental changes to existing drugs. This strategy provides short-term relief, but bacteria quickly develop resistance to these slight modifications. Seeking a long-term solution to this problem, Biolytx has developed an entirely new class of anti-infective treatments with a unique mechanism of action.